Avantor Strengthens Bioprocessing Position with Acquisition of Masterflex

Avantor has strengthened its offering across all bioproduction platforms with the acquisition of the Masterflex bioprocessing business and related assets of Antylia Scientific on Sept. 7, 2021. The acquisition was announced in a company press release.

Valued at $2.9 billion, the all-cash acquisition is still subject to final adjustments at closing and is expected to enhance Avantor’s offerings across all bioproduction platforms, including monoclonal antibodies (mAbs), cell and gene therapies, and messenger RNA. Additionally, it is expected that the acquisition will support both therapy and vaccine manufacturing, including COVID-19 offerings, for the company.

“The acquisition of Masterflex reflects our commitment to the biopharma industry, and our ability to identify and execute on value-creation opportunities,” said Michael Stubblefield, president and CEO of Avantor, in the company press release. “The business enhances our portfolio of proprietary technologies and strengthens our position in the highest growth segments of the market. Both Avantor and Masterflex share a strong culture of innovation and excellence, and we look forward to welcoming Masterflex's highly skilled team to the Avantor family.”

“This proposed transaction helps both parties and positions the Masterflex bioprocessing business well for future growth,” added Brian Barnett, president, Masterflex Bioprocessing, in the press release. “Avantor's broad portfolio is used in virtually every stage of the most important research, development, and production activities. We are excited about combining our end-to-end fluid management solution with Avantor's comprehensive portfolio of process ingredients, chromatography resins, and excipients for biopharma customers worldwide.”

Source: Avantor